[Skip to Content]
[Skip to Content Landing]
Views 4,595
Citations 0
Clinical Trials Update
June 25, 2019

Another Amyloid-beta Blocker Fails to Halt Dementia

JAMA. 2019;321(24):2396. doi:10.1001/jama.2019.7821

Verubecestat, an oral drug that blocks the production of amyloid-β, did not improve clinical ratings of dementia in patients with prodromal Alzheimer disease, according to a trial in the New England Journal of Medicine.

A total of 1454 participants with mild cognitive impairment and elevated brain amyloid levels were randomized to receive either 12 mg of verubecestat per day, 40 mg of verubecestat per day, or placebo. Cognitive decline was assessed using the Clinical Dementia Rating Scale—Sum of Boxes (CDR-SB), for which higher scores indicate worse outcomes. The trial was terminated for futility after 704 patients had completed the 104-week regimen.

×